Etoposide

CALQUENCE (Acalabrutinib) Emerging Drug Insights and Market Forecasts, 2019-2022 and 2023-2032: Focus on 7MM - United States, Germany, France, Italy, Spain, United Kingdom, and Japan - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 14, 2023

The "CALQUENCE Emerging Drug Insight and Market Forecast - 2032" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "CALQUENCE Emerging Drug Insight and Market Forecast - 2032" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • This report provides comprehensive insights about CALQUENCE for Diffuse Large B-cell lymphoma (DLBCL) in the seven major markets.
  • Further, it also consists of future market assessments inclusive of the CALQUENCE market forecast analysis for DLBCL in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in DLBCL.
  • A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of CALQUENCE in DLBCL.

Takeda to Present Data at 65th American Society of Hematology (ASH) Annual Meeting, Demonstrating Continued Commitment to Patients with Hematologic Diseases

Retrieved on: 
Monday, November 27, 2023

Takeda (TSE:4502/NYSE:TAK) today announced that it will present 17 company-sponsored abstracts at the 65th American Society of Hematology (ASH) Annual Meeting being held December 9-12, 2023 in San Diego.

Key Points: 
  • Takeda (TSE:4502/NYSE:TAK) today announced that it will present 17 company-sponsored abstracts at the 65th American Society of Hematology (ASH) Annual Meeting being held December 9-12, 2023 in San Diego.
  • Takeda’s latest research focuses on improving treatment options for those living with hematologic diseases.
  • “Our aspiration is to deliver life-transforming medicines for difficult-to-diagnose, rare hematologic diseases with high unmet patient need,” said Björn Mellgård, M.D., Ph.D., vice president and global program lead of Rare Genetics and Hematology at Takeda.
  • “Our continued research aims to improve long-term outcomes for patients suffering from these conditions.

OncoHost's PROphet® Platform to Support Henlius US-Based Phase III Trial for Patients with Extensive-Stage Small Cell Lung Cancer

Retrieved on: 
Tuesday, October 3, 2023

BINYAMINA, Israel , Oct. 3, 2023 /PRNewswire/ -- OncoHost, a technology company transforming the approach to precision medicine for improved patient outcomes, today announced a collaboration with Hengenix Biotech, Inc. (Henlius USA), affiliated with Shanghai Henlius Biotech, Inc., a global biopharmaceutical company with the vision to offer high-quality, affordable, and innovative biologic medicines for patients worldwide with a focus on oncology, autoimmune diseases, and ophthalmic diseases. Henlius USA will utilize OncoHost's PROphet® platform to identify exploratory, correlative biomarkers for patients recruited in its comprehensive Phase III clinical trial (NCT05468489). The trial is evaluating the efficacy and safety of Serplulimab plus chemotherapy (carboplatin - etoposide) in previously untreated US-based patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC).

Key Points: 
  • Henlius USA will utilize OncoHost's PROphet® platform to identify exploratory, correlative biomarkers for patients recruited in its comprehensive Phase III clinical trial ( NCT05468489 ).
  • The trial is evaluating the efficacy and safety of Serplulimab plus chemotherapy (carboplatin - etoposide) in previously untreated US-based patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC).
  • "Our shared goal is to improve cancer patients' outcomes by developing robust, scientifically sound technologies to support them and their caregivers.
  • We believe that such collaborations hold the potential to bring new hope to those affected by this challenging disease."

AUA Releases Amendment to the Diagnosis and Treatment of Early-Stage Testicular Cancer Guideline

Retrieved on: 
Thursday, September 14, 2023

BALTIMORE, Sept. 14, 2023 /PRNewswire/ -- Today the American Urological Association (AUA) released the 2023 clinical practice guideline amendment for the diagnosis and treatment of early-stage testicular cancer.

Key Points: 
  • BALTIMORE, Sept. 14, 2023 /PRNewswire/ -- Today the American Urological Association (AUA) released the 2023 clinical practice guideline amendment for the diagnosis and treatment of early-stage testicular cancer.
  • Testicular cancer is the most common solid malignancy in young males and is relatively rare, with outcomes defined by specific cancer and patient-related factors.
  • "Since the last testicular cancer guideline was released, the model for management has substantially changed, making an amendment like this critical to effectively treat and manage testicular cancer."
  • Diagnosis and treatment of early-stage testicular cancer: AUA Guideline amendment 2023.

Genprex Receives U.S. FDA Fast Track Designation for REQORSA® Immunogene Therapy in Combination with Tecentriq® for the Treatment of Small Cell Lung Cancer

Retrieved on: 
Wednesday, June 28, 2023

AUSTIN, Texas, June 28, 2023 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) for the Company's lead drug candidate, REQORSA® Immunogene Therapy, in combination with Genentech, Inc.'s Tecentriq® in patients with extensive-stage small cell lung cancer (ES-SCLC) who did not develop tumor progression after receiving Tecentriq and chemotherapy as initial standard treatment.

Key Points: 
  • We look forward to accelerating the clinical development of REQORSA, and potentially providing a new treatment option for patients with SCLC."
  • Virtually 100% of small cell lung cancers express decreased amounts of TUSC2 tumor suppressor protein, and 41% completely lack TUSC2 protein expression.
  • "This Fast Track Designation for the Acclaim-3 patient population is another validation of REQORSA's potential to treat lung cancer," said Mark Berger, MD, Chief Medical Officer at Genprex.
  • In addition, Fast Track product candidates could be eligible for priority review if supported by clinical data at the time of BLA submission.

Phase 3 Trial of ADCETRIS® (brentuximab vedotin) with Modified Chemo Regimen Shows Non-Inferiority with Unprecedented 3-Year Progression Free Survival of 94.9% vs Less Tolerable International Standard of Care in Advanced Classical Hodgkin Lymphoma

Retrieved on: 
Tuesday, June 20, 2023

The data results of the HD21 study were presented in a late-breaking session at the 17th International Conference on Malignant Lymphoma (ICML) in Lugano, Switzerland on June 17.

Key Points: 
  • The data results of the HD21 study were presented in a late-breaking session at the 17th International Conference on Malignant Lymphoma (ICML) in Lugano, Switzerland on June 17.
  • 12-month post-treatment safety data were consistent with previously presented HD21 data results at the American Society of Hematology 2022 Annual Meeting.
  • Preservation of fertility potential was indicated by measurement of follicle-stimulating hormone (FSH) and was available for 597 patients.
  • Please see Important Safety Information, including a BOXED WARNING for progressive multifocal leukoencephalopathy (PML), for ADCETRIS below.

Nurix Therapeutics Presents Data from Studies of Its Targeted Protein Degraders in B Cell Malignancies and Initiates Expansion of NX-2127 Phase 1b Trial in Diffuse Large B Cell Lymphoma and Mantle Cell Lymphoma Indications

Retrieved on: 
Wednesday, June 14, 2023

SAN FRANCISCO, June 14, 2023 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies and solid tumors, today announced the presentation of clinical and preclinical data from its targeted protein degradation programs, NX-5948 and NX-2127, which are being evaluated in ongoing Phase 1 clinical trials in patients with relapsed/refractory B cell malignancies. These data are being presented at the 17th International Conference on Malignant Lymphoma (ICML) which is being held June 13-17, in Lugano, Switzerland.

Key Points: 
  • These data are being presented at the 17th International Conference on Malignant Lymphoma (ICML) which is being held June 13-17, in Lugano, Switzerland.
  • Limitations of current covalent and non-covalent BTK inhibitors include the susceptibility to mutational escape as a basis for resistance.
  • Nurix’s BTK degraders have the potential to address these limitations of BTK inhibitors and provide a new therapeutic option for patients.
  • Nurix is announcing plans to initiate two new Phase 1b dose expansion cohorts in the ongoing Phase 1a/1b clinical trial of NX-2127 in patients with relapsed or refractory B-cell malignancies.

China Cancer Antibodies Market Trends & Clinical Trials Insight Report 2023: Clinical Trials Insight By Phase, Indication, Location, Companies, Licensee, Mono/Combination Therapy Approach - ResearchAndMarkets.com

Retrieved on: 
Monday, June 5, 2023

The "China Cancer Antibodies Market Trends & Clinical Trials Insight 2023" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "China Cancer Antibodies Market Trends & Clinical Trials Insight 2023" report has been added to ResearchAndMarkets.com's offering.
  • The current antibodies pipeline in China is still in the expansion phase as both domestic and international drug developers are continuously foraying into the market.
  • At present, multiple cancers are dominating the antibody clinical trials landscape in China similar to other developed pharmaceutical markets.
  • Clinical Trials Insight By Phase, Indication, Location, Companies, Licensee, Mono/Combination Therapy Approach

Advances of Qilu Pharmaceutical's QL1706 in Clinical Research Presented at ASCO Annual Meeting

Retrieved on: 
Wednesday, May 31, 2023

JINAN, China, May 31, 2023 /PRNewswire/ -- The American Society of Clinical Oncology (ASCO) recently announced the selected abstracts for the prestigious ASCO 2023 Annual Meeting.

Key Points: 
  • JINAN, China, May 31, 2023 /PRNewswire/ -- The American Society of Clinical Oncology (ASCO) recently announced the selected abstracts for the prestigious ASCO 2023 Annual Meeting.
  • Four clinical research abstracts on QL1706 (iparomlimab/tuvonralimab), an innovative bifunctional antibody for immunotherapy, were accepted in the Poster Session.
  • Two of the posters focus on the latest clinical research progress of Qilu Pharmaceutical's QL1706 in extensive-stage small cell lung cancer (ES-SCLC) and advanced hepatocellular carcinoma (HCC).
  • These findings support further investigation of QL1706 plus bevacizumab for first-line treatment of advanced HCC in a phase III clinical trial.

Extensive Stage Small Cell Lung Cancer Global Market Report 2022: Approval of Immune Checkpoint Inhibitors as Combination Therapy Broadens the Horizon - ResearchAndMarkets.com

Retrieved on: 
Monday, December 19, 2022

Extensive stage small cell lung cancer is extremely aggressive sub-type of small cell lung cancer.

Key Points: 
  • Extensive stage small cell lung cancer is extremely aggressive sub-type of small cell lung cancer.
  • Since, the introduction of immune checkpoint inhibitors to the extensive stage small cell lung cancer treatment, the competition in the global extensive stage small cell lung cancer market has significantly increased.
  • There is a rich clinical pipeline of extensive stage small cell lung cancer market with dominance of immune checkpoint inhibitors along with bispecific antibodies.
  • Competitive Strategy: Key players in the global extensive stage small cell lung cancer market were analyzed and profiled in the study, who have commercially available treatment for extensive stage small cell lung cancer.